56 Results for "

Myelodysplastic syndromes

" in MedChemExpress (MCE) Product Catalog:
Products (56)

56 Results for "Myelodysplastic syndromes" in MCE Product Catalog:

63
63 Publications Verification
Cat. No.: HY-A0003
CAS No.: 191732-72-6
Synonyms: CC-5013
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
loading...
    loading...
63
63 Publications Verification
Cat. No.: HY-A0003B
CAS No.: 847871-99-2
Synonyms: CC-5013 hemihydrate
Lenalidomide hemihydrate (CC-5013 hemihydrate) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide hemihydrate induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide hemihydrate promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide hemihydrate can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-15229
CAS No.: 929904-85-8
Purity:  98.04%
Synonyms: SGI-110 sodium; S-110 sodium
Target:  

DNA Methyltransferase

Research Areas:  

Cancer

Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-13634A
CAS No.: 168682-53-9
Purity:  99.71%
Synonyms: TER199free base; TLK199
Research Areas:  

Cancer

Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114226
CAS No.: 1887014-12-1
Purity:  99.16%
Synonyms: FT-2102
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10406
CAS No.: 309913-83-5
Purity:  98.68%
Synonyms: SCIO-469
Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16782
CAS No.: 945614-12-0
Synonyms: ARRY-614
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113061
CAS No.: 1445-07-4
Purity:  99.93%
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
loading...
    loading...
Cat. No.: HY-159520
CAS No.: 2731294-23-6
Synonyms: Ofirnoflast; HT-6184
Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-159646
CAS No.: 2564486-44-6
BMS-986397 is a potent, selective, and orally active cereblon-based molecular glue degrader of casein kinase 1α (CK1α). BMS-986397 induces apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. BMS-986397 is a promising agent for the investigation of AML and high-risk myelodysplastic syndromes (HR-MDS) .
loading...
    loading...
Cat. No.: HY-P99521
CAS No.: 2138442-13-2
Synonyms: XmAb14045

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
loading...
    loading...
Cat. No.: HY-P99555
CAS No.: 1449294-76-1
Synonyms: OPN-305
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
loading...
    loading...
Cat. No.: HY-156794
CAS No.: 2412555-70-3
Purity:  99.88%
Synonyms: DSP-5336
Research Areas:  

Cancer

Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
loading...
    loading...
Cat. No.: HY-145729
CAS No.: 1402357-06-5
Purity:  97.96%
Synonyms: AZD9150
Target:  

STAT Apoptosis

Research Areas:  

Cancer

Danvatirsen (AZD9150) is an antisense oligonucleotide targeting STAT3. Danvatirsen reduces the viability and promotes apoptosis of leukemia cell lines. Danvatirsen inhibits the expression of endogenous STAT3 and its downstream target genes, and reduces the proliferation and tumorigenicity of neuroblastoma and lymphoma cells. Danvatirsen inhibited tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma. Danvatirsen can be used in research related to lymphoma, myelodysplastic syndrome, acute myeloid leukemia, neuroblastoma and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99445
CAS No.: 1450882-18-4
Synonyms: APG101; CAN008

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
loading...
    loading...
Cat. No.: HY-N2907
CAS No.: 479-20-9
Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions .
loading...
    loading...
Cat. No.: HY-12854
CAS No.: 868169-64-6
Purity:  99.43%
Synonyms: GRN163L
Target:  

Telomerase Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .
loading...
    loading...
Cat. No.: HY-16018
CAS No.: 1227939-82-3
Synonyms: ABT-348
Target:  

Aurora Kinase VEGFR PDGFR

Research Areas:  

Cancer

Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
loading...
    loading...
Cat. No.: HY-16018A
CAS No.: 1847485-91-9
Synonyms: ABT-348 hydrochloride
Target:  

Aurora Kinase PDGFR VEGFR

Research Areas:  

Cancer

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
loading...
    loading...
Cat. No.: HY-P990009
CAS No.: 2649854-92-0
Synonyms: NIS-793

Research Areas:  

Cancer

Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody and an inhibitor of the TGF-β signaling pathway. Nisevokitug blocks the binding of TGF-β to the membrane-bound TGF-βR1/TGF-βR2 receptors, inhibits both Smad-dependent and Smad-independent downstream cascade signaling, downregulates fibrosis-related genes, and reverses the TGF-β-mediated immunosuppressive microenvironment. Nisevokitug can be used in the research of diseases such as pancreatic ductal adenocarcinoma, colorectal cancer, myelofibrosis, and myelodysplastic syndrome .
loading...
    loading...